EUCTR2016-001022-34-ES进行中（未招募）1 期
A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndrome - A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012
AVIZOREX PHARMA, S.L.0 个研究点目标入组 172 人开始时间: 2016年7月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients will be included in the study if all of the following criteria are met:
- •Male or female subjects of at least 18 years of age.
- •Diagnosis of dry eye (by a health care professional) for at least 3 months prior to screening visit.
- •Normal lid anatomy.
- •Intraocular pressure less than 22 mmHg (inclusive) in each eye.
- •Best-corrected visual acuity measured by ETDRS in each eye of 20/200 (logMAR 1.0) or better.
- •Schirmer I test score of = 3 mm to = 9 mm/ 5 min (with anesthesia).
- •SANDE symptom score of 50 or more.
- •Total ocular staining of minimum 1 in Oxford scale with fluorescein and/or green lissamine.
- •Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 172
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria will be defined ensuring that both ophthalmic and systemic criteria disqualify inappropriate subjects from inclusion in the clinical study.
- •Patients will be excluded for participating in this study if 1 or more of the following criteria are met:
- •Ophthalmic criteria:
- •1.History of other than dry eye, ocular surface of moderate to severe Meibomian gland disease (grades +++ to ++++ [moderately to severely altered expressibility and secretion quality]: moderate symptoms with mild to moderate corneal staining, mainly peripheral; or marked symptoms with marked corneal staining, central in addition), chronic, or acute ophthalmic disease in either eye, including glaucoma, macular degeneration, clinically significant cataract (primary or secondary).
- •2.Best-corrected visual acuity score of 55 letters read or lower in each eye as measured by ETDRS (letters read method).
- •3.Any hypersensitivity to the use of the study product formulations or an allergy to any ingredient(s) contained within product formulations or products required while participating in the study, such as sodium fluorescein.
- •4.Intraocular, strabismus, or palpebral surgery or surgery in the orbit or glaucoma laser surgery within the previous 6 months.
- •5.History of refractive surgery in either eye (e.g., radial keratotomy, PRK, LASIK, etc.).
- •6.Ocular trauma within the past 6 months.
- •7.Ocular surgery or laser treatment within the past 3 months.
- •8.Evidence of ocular abnormalities in either eye that could adversely affect the safety or efficacy outcome such as:
- •?Eyelid anomalies that affect proper lid closure or proper blink function (e.g., ectropion or entropion).
- •?Corneal disorders or abnormality such as active corneal ulcer, current corneal abrasion, keratoconus, or corneal dystrophies which are actively changing or affect vision.
- •?Metaplasia of the ocular surface.
- •?Current filamentous keratitis.
- •?Evidence of corneal neovascularization.
- •?Any history of herpes simplex or herpes zoster keratitis.
- •?Ocular infection (bacterial, viral, or fungal), inflammation not associated with dry eye such as uveitis, iritis, active blepharitis, active allergic conjunctivitis, etc., cystoid macular edema.
- •9.Ocular medication of any kind, with the exception of artificial tears/gels/lubricants within the past 2 weeks of screening. Note: a minimum 90-day washout period from use of Restasis® or Ikervis® will be required.
- •10.Use of systemic medication that might cause dryness in the eye as a secondary effect (such as antihistaminics, hormone replacing therapies, etc.).
- •11.Contact lens use within 2 weeks prior to screening visit and/or unwilling to avoid contact lens use during the course of the study.
- •12.Unwilling to avoid use of additional artificial tears (other than study treatments) throughout the study, starting at screening visit.
- •13.Participation in an investigational drug or device trial within the 30 days previous to screening visit.
- •14.Any abnormality preventing reliable applanation tonometry of either eye.
- •15.Central corneal thickness gr
研究者
相似试验
进行中（未招募）
不适用
A controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgeryPost-operative pain after laparoscopic colon or rectum surgery in fast-track designMedDRA version: 14.1Level: LLTClassification code 10036236Term: Postoperative pain reliefSystem Organ Class: 100000004865EUCTR2010-021604-16-DECharité Universitätsmedizin Berlin
进行中（未招募）
1 期
A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience seizures.Tuberous Sclerosis Complex (TSC)MedDRA version: 21.0Level: LLTClassification code 10045138Term: Tuberous sclerosisSystem Organ Class: 100000004850EUCTR2015-002154-12-PLGW Research Ltd.224
招募中
3 期
Ashwagandha and Selenium combination as a supplement in patients with subclinical hypothyroidismCTRI/2023/07/054940Sami Sabinsa Group Limited
尚未招募
2 期
A study to evaluate the efficacy of Eclipta prostrata (L.) L. in the treatment of atopic dermatitis in childreAtopic dermatitsC16.320.850RBR-2fqcbrxFaculdade de Medicina de Ribeirão Preto da Universidade de São Paulo - USP
进行中（未招募）
1 期
A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience seizures.Tuberous Sclerosis Complex (TSC)MedDRA version: 20.0Level: PTClassification code 10045138Term: Tuberous sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-002154-12-NLGW Research Ltd.210